DUSP6 and neoplasm: The human xenograft studies required immunodeficient mice and thus we turned to a new transgenic PDAC mouse model, KDC (PdxCre+KRasLSL‐G12D/+dusp6−/−), which combines a RasG12D mutation with loss of dual‐specific phosphatase 6 (Dusp6), considered a potential tumour suppressor in PDAC 31; in KDC mice, αvβ6 was expressed in PanINs and PDAC tumours (Figure 5).